ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study

BACKGROUND: Randomized trials have demonstrated that anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) can be safe and efficacious treatments for patients with ALK-positive advanced non-small-cell lung cancer (aNSCLC). However, their safety, tolerability, effectiveness, and patterns...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Michelle, Slatter, Shadera, Sussell, Jesse, Lin, Chia-Wei, Ogale, Sarika, Datta, Debajyoti, Butte, Atul J., Bazhenova, Lyudmila, Rudrapatna, Vivek A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345061/
https://www.ncbi.nlm.nih.gov/pubmed/37341856
http://dx.doi.org/10.1007/s11523-023-00973-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345061/
https://www.ncbi.nlm.nih.gov/pubmed/37341856
http://dx.doi.org/10.1007/s11523-023-00973-7

Ejemplares similares